World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
38765
World Ranking
7656
National Ranking
3987

Overview

Gautam Borthakur is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine, with a specialization in hematology, genetics, molecular biology, public health, environmental and occupational health, and oncology.

The main topics of their work include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Histone Deacetylase Inhibitors Research
  • Acute Lymphoblastic Leukemia research
  • Protein Degradation and Inhibitors

Frequent co-authors in their body of work are:

  • Tapan M. Kadia
  • Farhad Ravandi
  • Hagop M. Kantarjian
  • Courtney D. DiNardo
  • Guillermo Garcia-Manero

Borthakur has contributed to numerous scientific publications, appearing often in journals such as Blood, Clinical Lymphoma Myeloma & Leukemia, American Journal of Hematology, Journal of Clinical Oncology, and Cancer.

Notable recent papers include:

  • Acute myeloid leukemia: current progress and future directions, 2021, Blood Cancer Journal
  • Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges, 2020, Cancer Discovery
  • Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia, 2021, Journal of Clinical Oncology
  • 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial, 2020, The Lancet Haematology
  • De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017, 2021, Cancer

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

    Daniel J. Klionsky;Amal Kamal Abdel-Aziz;Sara Abdelfatah;Mahmoud Abdellatif

  • Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

    Rongqing Pan;Leah J. Hogdal;Juliana M. Benito;Donna Bucci

  • Acute myeloid leukemia: current progress and future directions.

    Hagop Kantarjian;Tapan Kadia;Courtney DiNardo;Naval Daver

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

    Alfonso Quintás-Cardama;Hagop Kantarjian;Taghi Manshouri;Rajyalakshmi Luthra

  • Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

    Farhad Ravandi;Jorge E Cortes;Daniel Jones;Stefan H Faderl

  • Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

    Jorge E. Cortes;Hagop Kantarjian;James M. Foran;Darejan Ghirdaladze

  • Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

    Hagop M. Kantarjian;Susan OBrien;Elias Joseph Jabbour;Guillermo Garcia-Manero

  • Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

    Farhad Ravandi;Mona Lisa Alattar;Michael R. Grunwald;Michelle A. Rudek

  • Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment

    Roland B. Walter;Roland B. Walter;Megan Othus;Gautam Borthakur;Farhad Ravandi

  • First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia

    Farhad Ravandi;Susan O'Brien;Deborah Thomas;Stefan Faderl

  • Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality

    Jo Ishizawa;Sarah F. Zarabi;Sarah F. Zarabi;R. Eric Davis;Ondrej Halgas;Ondrej Halgas

  • Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.

    Nitin Jain;Audrey V. Lamb;Susan O’Brien;Farhad Ravandi

  • Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

    Jorge E. Cortes;Dan Jones;Susan O'Brien;Elias Jabbour

  • The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

    Francis J. Giles;Francis J. Giles;Gautam Borthakur;Farhad Ravandi;Stefan Faderl

  • Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

    Jorge E. Cortes;Dan Jones;Susan O'Brien;Elias Jabbour

  • Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.

    Koji Sasaki;Koji Sasaki;Sara S Strom;Susan O'Brien;Elias Jabbour

  • Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

    Alireza Eghtedar;Srdan Verstovsek;Zeev Estrov;Jan Burger

  • A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

    Stefan Faderl;Farhad Ravandi;Xuelin Huang;Guillermo Garcia-Manero

  • Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel

    Wendy Stock;Dan Douer;Daniel J. Deangelo;Martha Arellano

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Naval Daver
Naval Daver The University of Texas MD Anderson Cancer Center
Marina Konopleva
Marina Konopleva The University of Texas MD Anderson Cancer Center
Sherry Pierce
Sherry Pierce The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a future in Medicine often opens the door to various related career paths within healthcare. For those interested in administration, pursuing the cheapest online healthcare administration degree is a budget-friendly way to enter management and leadership roles in medical settings. If you’re seeking to advance even further, the cheapest mha online programs offer a flexible pathway to a graduate degree, preparing graduates for upper-level positions in hospitals, clinics, and other organizations.

For those aiming for clinical leadership, Doctor of Nursing Practice graduates are in high demand. You can review the best dnp programs online for comprehensive training in advanced practice nursing. Alternatively, if pharmaceutical care interests you, there are fully accredited pharm d online programs suitable for working professionals.

Exploring these affordable online degrees can expand your skillset, enhance your career potential, and make you more competitive in the rapidly evolving field of healthcare.

Best Scientists Citing Gautam Borthakur

Trending Scientists